Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 9/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17388662 | 1.00 | PIN1 (0.50) | PIN1ABL1BCRPOLBTDP1 | |
| SCHEMBL19665640 | 0.91 | HSD11B1 (0.47) | PIN1ABL1BCRPOLBTDP1 | |
| SCHEMBL14841407 | 0.89 | PIN1 (0.45) | PIN1ABL1BCRHSD11B1GSK3B | |
| SCHEMBL17388653 | 0.89 | PIN1 (0.45) | PIN1ABL1BCRHSD11B1GSK3B | |
| SCHEMBL1784631 | 0.88 | PIN1 (0.48) | PIN1ABL1BCRPOLBTDP1 | |
| SCHEMBL15974579 | 0.83 | PIN1 (0.41) | PIN1POLBHSD11B1KMT2AMAPT | |
| SCHEMBL1804937 | 0.82 | PIN1 (0.56) | PIN1GSK3BGSK3ACDK2KMT2A | |
| SCHEMBL17649495 | 0.81 | PIN1 (0.50) | PIN1POLBTDP1L3MBTL1GSK3B | |
| SCHEMBL20837955 | 0.81 | PIN1 (0.50) | PIN1POLBTDP1L3MBTL1GSK3B | |
| SCHEMBL19666697 | 0.81 | PIN1 (0.50) | PIN1POLBTDP1L3MBTL1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708326-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160002241-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, LLC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014130693-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002241-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | PIN1 2265/4885ABL1 6/4885BCR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.